Medicinal Cannabis & Glioblastoma Multiforme Treatment
About Webinar
In this engaging webinar, A/Prof Lacey will delve into the role of medicinal cannabis in the treatment of patients with Glioblastoma Multiforme (GBM), a highly malignant brain cancer with a poor prognosis. She will discuss the results of a phase II randomized trial and provide insights into current and future clinical trials.
The session will also explore how best to manage patients with high-grade gliomas using medicinal cannabis and offer a glimpse into preliminary survivorship data. This webinar aims to provide medical professionals with an understanding of the emerging role of medicinal cannabis in oncology, particularly for patients with GBM.
Learning Outcomes
- Current Research Overview: Gain an overview of the current research on the use of medicinal cannabis for patients with Glioblastoma Multiforme.
- Phase II Randomized Trial Results: Learn about the results of a phase II randomized trial involving medicinal cannabis and its implications.
- Current and Future Clinical Trials: Obtain information on ongoing and future clinical trials exploring the role of medicinal cannabis in treating GBM.
- Management of Patients: Understand best practices for managing patients with high-grade gliomas using medicinal cannabis.
- Preliminary Survivorship Data: Gain insights into preliminary survivorship data related to medicinal cannabis use in GBM treatment.
About the speaker

A/Prof Judith Lacey, MBBS, FRACGP, FAChPM (RACP), is the Head of Supportive Care and Integrative Oncology at Chris O’Brien Lifehouse Comprehensive Cancer Centre in NSW, Australia. She also serves as an Adjunct Associate Professor at the NICM Health Research Institute, Western Sydney University, and as a Senior Clinical Lecturer at the School of Medicine, University of Sydney.
A/Prof Lacey is dedicated to ensuring people living with cancer maintain the highest quality of life possible, gardless of prognosis or stage of disease, and her research activities span across integrative oncology, medicinal cannabis, and supportive care service development.
Claim 1 CPD Hour
Medihuanna is a CPD approved education provider, and this activity has been approved by the RACGP (Activity ID: 555572). Upon completing this activity, you will be eligible to claim CPD hours. The activity will include the following CPD allocation which will be uploaded to the RACGP dashboard.
-23-07-26.jpg)
Related content
Live Webinar19 Nov 2026, 07:00 PMPastilles in Clinical Practice: Optimising Precision Dosing, Adherence and Patient Outcomes
Explore the clinical role of cannabis pastilles, including precision dosing, patient selection, adherence, safety and the evolving evidence for major and minor cannabinoids.
Learn more
Live Webinar02 Dec 2026, 07:00 PMBeyond the Dose: Understanding Oral Cannabinoid Therapy
Explore how formulation, absorption and metabolism influence the bioavailability and clinical effects of oral THC and CBD. This webinar examines key pharmacokinetic principles, emerging delivery technologies and published evidence to inform formulation selection, dosing and patient monitoring.
Learn more
On-demand WebinarEmerging Therapeutics for Behavioural and Psychological Symptoms of Dementia
Explore evidence-based management of behavioural and psychological symptoms of dementia and the emerging role of cannabinoid-based medicines.
Learn more
On-demand WebinarTHCV and Metabolic Health: Exploring the Evidence and Clinical Potential
Explore the emerging role of Δ9-tetrahydrocannabivarin (THCV) in metabolic health, including its potential influence on appetite regulation, glucose metabolism and weight management. This session reviews THCV pharmacology, CB1 signalling, current preclinical and human evidence, and the key limitations shaping its potential future clinical application.
Learn more